Riskpilot← Back to searchSign inGet full accessPLEONOVA AB
ABActiveOrg 5565683835Stenkullavägen 26Legal activities · NACE 6910Est. 19990 employees
Revenue 2024
SEK 42K
+323% vs 2023
EBITDA margin
-629.2%
-10% vs 2023
Equity ratio
95.9%
Financial strength
Net profit 2024
SEK 253K
-87% vs 2023
| Revenue | SEK 42K | +323% |
| EBITDA | SEK -264K | -10% |
| Net profit | SEK 253K | -87% |
| Total assets | SEK 2,3M | -15% |
| Equity | SEK 2,2M | -14% |
| Employees | 0 | — |
Legal name
PLEONOVA AB
Org number
5565683835
Legal form
Aktiebolag
NACE code
6910 · Legal activities
Founded
19 mars 1999
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsult- och utvecklingsverksamhet inom biomedicin, författarverksamhet samt därmed förenlig verksamhet.
Address
Stenkullavägen 26
Email
hans.peter.ekre@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 62 | 2 | 79 | 10 | 42 |
| Staff expenses | — | — | −120 | −110 | −145 |
| EBITDA | −208 | −161 | −173 | −240 | −264 |
| Depreciation & amort. | −0 | −0 | — | — | −19 |
| EBIT | −208 | −161 | −173 | −240 | −283 |
| Net financials | −1 824 | −190 | −121 | 2 201 | 537 |
| Profit before tax | 909 | 429 | −294 | 2 004 | 253 |
| Tax | −28 | −0 | — | — | — |
| Net profit | 881 | 429 | −294 | 2 004 | 253 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 695 | 1 768 | 1 239 | 2 699 | 2 304 |
| Equity | 1 217 | 1 646 | 1 002 | 2 555 | 2 209 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 435 | 79 | 194 | 143 | 95 |
| Total debt | 435 | 79 | 194 | 143 | 95 |
EBITDA margin
-629.2%
This company
15.8%
Market median
-4082% vs market
20202024
Equity ratio
95.9%
This company
38.2%
Market median
+151% vs market
20202024
Return on equity
11.5%
This company
18.4%
Market median
+37% vs market
20202024
Net profit margin
604.5%
This company
8.1%
Market median
+7363% vs market
20202024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20202024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PLEONOVA AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Peter Torsten Ekre | Chief Executive Officer | 0 companies |
| Helen Katarina Spalding | Deputy Board Member | 0 companies |